Press Releases
Filters
March 19, 2026
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
February 26, 2026
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
February 25, 2026
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
February 3, 2026
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
January 20, 2026
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
January 8, 2026
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Displaying 1 - 10 of 184